LifeMine Therapeutics employs Top-Down Drug DiscoveryTM, utilizing evolutionary insights from fungi and advanced genomics to identify and develop precision medicines. The company focuses on high-impact disease targets, particularly in organ transplantation and antifungal treatments, to accelerate the delivery of novel therapeutics to patients in need.
Funding
$300.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FFounders
Product
Problem
Traditional "bottom-up" drug discovery methods struggle to translate the rapid advancements in human genomics and disease understanding into new medicines. This approach often fails to identify novel therapeutic targets and develop effective treatments for high-impact diseases.
Solution
LifeMine Therapeutics employs Top-Down Drug Discovery™, a novel approach that leverages evolutionary insights from fungi and advanced genomics to identify and develop precision medicines. This data-immersive and technologically expansive discovery engine enables the company to unearth next-generation therapeutics at scale. By focusing on mechanistically and structurally novel compounds, LifeMine aims to accelerate the delivery of breakthrough disease interventions to patients in urgent need. The company's initial pipeline programs are focused on organ transplantation and antifungals.
Target Audience
LifeMine's primary focus is on patients with high-impact diseases, particularly those in need of improved treatments for organ transplantation and fungal infections.
Features
- Top-Down Drug Discovery™ platform utilizing evolutionary insights from fungi
- Advanced genomics and data science for target identification
- Focus on mechanistically and structurally novel precision medicines
- Pipeline programs in organ transplantation and antifungals